NCT05359783View on ClinicalTrials.gov

Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

February 15, 2023

Study Completion Date

April 30, 2024

Conditions
Breast CancerSentinel Lymph Node
Interventions
DRUG

Superparamagnetic Iron Oxide

Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.

Trial Locations (1)

41345

Sahlgrenska University Hospital, Gothenburg

All Listed Sponsors
lead

Vastra Gotaland Region

OTHER_GOV

NCT05359783 - Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide | Biotech Hunter | Biotech Hunter